OraSure Technologies(NASDAQ:OSUR) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Company reported revenue of $31.36M. Analysts estimated a revenue of $31.15M. Earnings per share were $0.07. Analysts had estimated an EPS of $0.05.
In a different note, On Jun 13, 2016, Raymond James said it Downgrades its rating on OraSure Technologies. The shares have been rated ‘Market Perform’ by the firm.
OraSure Technologies (OSUR) shares turned negative on Fridays trading session with the shares closing down -0.08 points or -1.13% at a volume of 5,09,460. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $7.13. The peak price level was also seen at $7.13 while the days lowest was $6.92. Finally the shares closed at $6.97. The 52-week high of the shares is $7.99 while the 52-week low is $4.39. According to the latest information available, the market cap of the company is $388 M.
OraSure Technologies Inc. (OraSure) is involved in the development manufacture marketing and sale of oral fluid diagnostic products and specimen collection devices and other diagnostic products designed to detect or diagnose critical medical conditions. These products include OraQuick In-Home HIV Test OraQuick ADVANCE OraSure HIV-1 oral specimen collection device OraQuick HCV rapid antibody test Intercept oral fluid drug testing system OraSure QuickFlu Rapid Flu A&B Test and Q.E.D. Saliva Alcohol test. The Company also manufactures and sells a range of cryosurgical products. Through its wholly owned subsidiary DNA Genotek Inc. the Company provides oral fluid sample collection stabilization and preparation products for molecular diagnostic applications.